ABVC BioPharma, Inc. announced that it entered into a global licensing definitive agreement with AiBtl BioPharma Inc. (AiBtl) for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the "Licensed Products"). The agreement has the potential of licensing income worth $467 Million and royalties up to $200 million. The Licensed Products for MDD and ADHD, owned by ABVC and its subsidiary BioLite, Inc., were valued at $667 million by a third-party evaluation.

ABVC and AiBtl are determined to work to strengthen their new drug development and business collaboration. This definitive agreement brings licensing revenues for ABVC and its subsidiary BioLite, Inc. as AiBtl stock of 46 million shares worth $460M and milestone cash payments of $7 million with the royalties of 5% of net sales, up to $200 million, after the product's launch.